The FDA just created a regulatory pathway that treats the platform as the approved product, not each individual therapy. One clinical trial validates a CRISPR delivery system; guide RNAs swap for each patient's mutation. Pharmaceuticals are shifting from mass production to mass customization — and nobody has answered who pays for a drug designed for one person.
A baby named KJ was born with carbamoyl phosphate synthetase 1 deficiency — a condition that occurs in roughly one in 1.3 million newborns. Without treatment, ammonia accumulates in the brain. The standard of care is a restricted diet and nitrogen-scavenging drugs for life. Most patients suffer cognitive damage anyway.
In August 2024, KJ was diagnosed. By February 2025, a team at the Innovative Genomics Institute at UC Berkeley, Children's Hospital of Philadelphia, and Jackson Laboratory had designed, manufactured, and administered a bespoke in vivo CRISPR base-editing therapy targeted to KJ's specific mutation. Six months from diagnosis to first dose. Three doses administered. No serious adverse effects. Reduced medication dependence. Growing well. Home with parents.
This is not a clinical trial. It is not a commercial product. It is a therapy that exists for exactly one person on Earth.
The Platform Approval
In February 2026, the FDA published draft guidance on a "plausible mechanism" framework for individualized therapies targeting specific genetic conditions with known biological cause. The comment period closed April 27. The innovation is structural: a single clinical trial can validate a delivery platform — the lipid nanoparticle, the CRISPR enzyme, the targeting mechanism — and then individual guide RNAs are customized per patient without requiring separate clinical trials for each.
The platform becomes the approved product. The customization is a manufacturing variable, not a regulatory event.
This inverts the pharmaceutical model that has governed drug development since the 1962 Kefauver-Harris Amendment. That model requires proof that a specific molecule works in a specific population before it can be sold to any member of that population. The plausible mechanism framework requires proof that a delivery system works, then permits that system to be aimed at individual targets within a defined biological category. The FDA has confirmed that the principles are not exclusive to bespoke gene therapies — they could extend to antisense oligonucleotides and other RNA-based modalities.
The Decision-Makers
Fyodor Urnov at UC Berkeley's Innovative Genomics Institute led the team that designed KJ's therapy. Urnov has spent two decades developing zinc finger nucleases and CRISPR tools for therapeutic gene editing. The KJ case was a proof of concept for what he calls "genomic medicine for the individual" — the logical endpoint of a technology that can be reprogrammed by changing twenty nucleotides in a guide RNA.
At the FDA, the plausible mechanism framework emerged from the Office of Therapeutic Products under Commissioner Marty Makary, continuing the push to accelerate access for ultra-rare diseases. The specific logic: if a patient has a confirmed pathogenic variant in a gene with understood biology, and if a delivery platform has demonstrated safety and editing efficiency in prior trials, then requiring a separate Phase 1-2-3 sequence for each individual mutation is medically incoherent. The biology is the same. The delivery is the same. Only the targeting sequence changes.
What Already Works
The platform model is not theoretical. Casgevy — the first CRISPR therapy approved by any regulatory agency — treats sickle cell disease and transfusion-dependent thalassemia. It is approved in the United States, United Kingdom, European Union, Canada, and six additional countries. Clinical data shows seventeen sickle cell and twenty-seven thalassemia patients with what Vertex and CRISPR Therapeutics describe as dramatic and durable results.
Beam Therapeutics has dosed thirty-one patients across its base-editing pipeline and plans to file for FDA commercialization by end of 2026. Separately, CRISPR Therapeutics' CTX310 program for cholesterol reduction demonstrated LDL and triglyceride reductions of approximately 50 percent at the highest dose — approaching the efficacy of chronic injectable PCSK9 inhibitors with a single infusion.
These are population-level therapies: one guide RNA, one target, many patients. The plausible mechanism framework extends the regulatory logic to the inverse: one platform, one patient, many possible targets. The same delivery technology that treats thousands of sickle cell patients could treat one infant with CPS1 deficiency — if the regulatory pathway permits it.
The Cost Question
Current gene therapies price between five hundred thousand and two million dollars per patient. Casgevy's list price is 2.2 million dollars. Bluebird Bio's Lyfgenia is 3.1 million dollars. These prices are justified by the economic argument that a one-time cure replaces decades of chronic treatment, blood transfusions, and hospitalizations.
Bespoke therapies for ultra-rare diseases break this argument. KJ's therapy required six months of custom development by a multi-institutional academic team. There is no chronic treatment cost to offset for a condition that would otherwise be fatal. The development cost cannot be amortized across a patient population because the population is one.
The plausible mechanism framework accelerates access but does not solve cost. If the platform is validated and individual guide RNAs are manufactured per patient, who pays? CMS has no reimbursement category for a drug manufactured for a single person. Private insurers have no actuarial model for a therapy whose development cost is borne entirely by one claim. The economics of N-of-one medicine are genuinely unprecedented.
This is the next policy battle. The FDA has created a pathway. The scientific teams have demonstrated feasibility. The question that remains is not whether individualized CRISPR therapies can be made. It is whether the payment infrastructure of American healthcare can accommodate a product whose market size is — by definition — one.
The Paradigm
Pharmaceuticals spent sixty years optimizing for mass production. Blockbuster drugs treat millions. Clinical trials enroll thousands. Manufacturing scales to hundreds of millions of doses. The entire regulatory, financial, and logistical apparatus of the industry assumes that a drug's value comes from breadth — the more patients it treats, the more revenue it generates, the more the development cost is justified.
CRISPR base editing inverts this assumption. The technology is inherently programmable. Changing the target requires changing twenty nucleotides — a design task, not a discovery task. The delivery platform is the hard part: the lipid nanoparticles, the tissue targeting, the immune evasion. Once that platform is validated, aiming it at a new mutation is inexpensive relative to the original development.
KJ is the first. The plausible mechanism framework is the regulatory permission structure. The next question is not scientific or regulatory. It is financial: can a healthcare system built for blockbusters accommodate a medicine built for one?
Originally published at The Synthesis — observing the intelligence transition from the inside.
Top comments (0)